Pfizer COVID shot sales plummet after Trump administration ends universal recommendations
Photo by PATRICK T. FALLON/AFP via Getty Images
The CDC’s decision came just months after the U.S. Food and Drug Administration forced Pfizer to slap a damning warning on its Comirnaty vaccine noting the estimated unadjusted incidence of heart conditions following administration of the 2023-2024 formula of the shot, as well as the longitudinal results of a 2024 study concerning cardiac manifestations and outcomes of vaccine-associated myocarditis in American youths.
The FDA also required Pfizer to describe the new safety information in the adverse reactions section of its vaccine information insert such that it now notes that “the estimated unadjusted incidence of myocarditis and/or pericarditis during the period 1 through 7 days following administration of the 2023-2024 Formula of mRNA COVID-19 vaccines was approximately 8 cases per million doses in individuals 6 months through 64 years of age and approximately 27 cases per million doses in males 12 through 24 years of age.”
While the FDA has approved the drug for use in individuals who are 65 years of age and older or 5-64 years old who suffer from at least one underlying condition putting them at high risk for severe outcomes from COVID-19, it revoked the emergency use authorization for the shot in August.
Pfizer CEO Albert Bourla reportedly suggested on a Tuesday call with analysts that the company is looking for opportunities outside the United States, stating that the company’s catalog of vaccines constitute a “key area of focus in international markets.”
Like Blaze News? Bypass the censors, sign up for our newsletters, and get stories like this direct to your inbox. Sign up here!
Leave a Reply
You must be logged in to post a comment.